Six-month versus nine-month therapy for intestinal tuberculosis: a protocol for a randomized controlled study
| Autor: | Hong Xu, Cheng Er Zhan, Jianyong Chen, Xia Jiang, Zhao Lin Zhang, Li Zhao, Dongya Chen, Min Liu, Linlin Shi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Every Three Months Tuberculosis Lymph Node INTESTINAL TUBERCULOSIS law.invention Treatment and control groups Randomized controlled trial law Internal medicine medicine Clinical endpoint Humans Multicenter Studies as Topic Randomized Controlled Trials as Topic Advanced and Specialized Nursing Protocol (science) medicine.diagnostic_test SARS-CoV-2 business.industry COVID-19 medicine.disease Tuberculous lymphadenitis Endoscopy Treatment Outcome Anesthesiology and Pain Medicine business |
| Zdroj: | Annals of Palliative Medicine. 10:9233-9238 |
| ISSN: | 2224-5839 2224-5820 |
| DOI: | 10.21037/apm-21-1642 |
| Popis: | BACKGROUND: The optimal duration of treatment for intestinal tuberculosis (TB), which remains a common disease worldwide, has not yet been established. The proposed randomized controlled study will aim to compare the efficacy of short-term six-month with nine-month anti-TB therapy for treating intestinal TB. METHODS: This multicenter, open-label, double-blinded, randomized controlled trial conducted in the Affiliated Hangzhou Chest Hospital of Zhejiang University will include a total of 80 patients. Patients who meet the inclusion criteria will be randomly assigned to either the six-month (n=40) or nine-month (n=40) treatment group. The primary outcome will be complete response, which is defined as endoscopy displaying active lesion healing at the end of treatment. Participants will be scheduled for follow-up visits once a month in the first three months, then once every three months until the end of the treatment. The last follow-up will be one year after the treatment. Recurrence will be assessed one year after the end of treatment, which is defined as endoscopy displaying recurrent lesions after complete response. DISCUSSION: In addition to the reports of tuberculous lymphadenitis and spinal TB, there are few appropriate randomized trials for the treatment of extrapulmonary TB with appropriate clinical endpoints. We believe that the proposed randomized controlled trial will provide further data on the efficacy of short-term six-month anti-TB therapy in intestinal TB patients. TRIAL REGISTRATION: This trial will be registered on ClinicalTrial.gov. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|